Patients with evidence of active brain metastases, or active leptomeningeal disease are ineligible; patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) prior to enrollment Patients with metastases Active brain metastases or leptomeningeal metastases Subjects with known symptomatic brain metastases or leptomeningeal metastases No active intracranial metastases Participants must not have active brain metastases or leptomeningeal metastases Uncontrolled central nervous system (CNS) metastases, including leptomeningeal metastases, are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been stable without steroid treatment for at least weeks (radiotherapy or surgery) Patients are excluded if they have active brain metastases or leptomeningeal metastases; subjects with brain metastases are eligible if metastases have been treated and there is no imaging evidence of progression for days after treatment is complete and within days prior to the first dose of nivolumab administration Patients may have metastases, with newly identified peripheral metastases Primary central nervous system (CNS) malignancies or CNS metastases, including leptomeningeal metastases, are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been stable for at least months following prior treatment (radiotherapy or surgery) Known active brain or leptomeningeal metastases (defined as symptomatic metastases) or continued requirement for glucocorticoids for brain or leptomeningeal metastases; treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least weeks prior to day of study drug Patients with known brain metastases or leptomeningeal metastases should be excluded from this clinical trial; patients with other extrapleural metastases are included in this study Patients with cerebral metastases Patients with active brain metastases or leptomeningeal metastases Patients are excluded if they have active brain metastases or leptomeningeal metastases; subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for days prior to initiation of treatment Patients are excluded if they have active, symptomatic brain metastases or leptomeningeal metastases; subjects with known brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for four weeks (after treatment is complete and within days prior to study drug administration) Patients with cerebral metastases Subjects must not have clinically active cerebral metastases. Active brain metastases or leptomeningeal metastases are not allowed. Active brain metastases or leptomeningeal metastases Active brain metastases or leptomeningeal metastases Any brain metastases including leptomeningeal metastases, are excluded, even if treated and stable. Subjects with active brain metastases or leptomeningeal metastases Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease Brain metastases, leptomeningeal disease or bone metastases Clinically active cerebral metastases. Uncontrolled central nervous system (CNS) metastases, including leptomeningeal metastases, are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been stable without steroid treatment for at least weeks following prior treatment (radiotherapy or surgery) Active brain metastases or leptomeningeal metastases are not allowed Leptomeningeal metastases or brain metastases except as for Inclusion Criterion #. Active brain metastases or leptomeningeal metastases Active metastases. Active central nervous system metastases. Patients with a history of brain metastases may be eligible, provided they have been definitively treated and are clinically stable, after discussion with sponsor. Treated or untreated leptomeningeal disease is not permitted. Active brain metastases or leptomeningeal metastases (carcinomatous meningitis); subjects with brain metastases are eligible if these have been treated and there is no evidence of progression for at least weeks after treatment is complete and corticosteroid dose is stable (and equivalent dose of < mg prednisone) for at least weeks Active metastases. Subjects with leptomeningeal metastases may or may not have brain metastases. When brain metastases are present, they do not need to have progressed after radiation therapy Active brain metastases (untreated brain metastases or growth on imaging as defined below) or leptomeningeal disease are not allowed; subjects with brain metastases are eligible if these have been treated and there is no MRI (or CT if MRI contraindicated) evidence of progression for at least weeks after treatment for these metastases is complete and within days prior to first study treatment Active brain metastases or leptomeningeal metastases Uncontrolled central nervous system (CNS) metastases are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade or baseline and steroids are no longer required; leptomeningeal metastases are not allowed For lung metastases, no more than metastases treated in one setting Subjects with active brain metastases or leptomeningeal metastases Has active brain metastases or leptomeningeal metastases.